Special Issue "PI3 Kinase Inhibitors"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 June 2012)
Dr. Philip Thompson
Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical, Sciences, Monash University, Parkville 3052, Australia
Phosphoinositide 3-kinases (PI3K) are important cell signalling enzymes, generating key second messengers that regulate a myriad of cellular functions. In recent years, potential applications for inhibitors have emerged in the treatment of cancer, cardiovascular disease, inflammatory diseases and autoimmune diseases. This special issue hopes to highlight the challenges and lessons learned in going from "hit to lead" and "lead to candidate" when developing targets for PI3K. Articles that deal with the concepts and results of specific strategic choices in PI3K inhibitor pharmaceutical development are encouraged. These include design approach (eg library screening, structure based design), isoform selectivity, scaffold selection, ADME properties or in vitro/in vivo models. In this issue, I hope novel contributions can be made to the medicinal chemistry knowledge base with original papers or critical reviews.
Dr. Philip Thompson
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- PI3 kinase
- cell signaling
- cancer therapeutics
- lipid kinase
- immune disease
Review: The Phosphatidylinositol 3-Kinase/mTor Pathway as a Therapeutic Target for Brain Aging and Neurodegeneration
Pharmaceuticals 2011, 4(8), 1070-1087; doi:10.3390/ph4081070
Received: 12 May 2011; in revised form: 22 July 2011 / Accepted: 28 July 2011 / Published: 4 August 2011| Download PDF Full-text (550 KB) | Download XML Full-text
Pharmaceuticals 2012, 5(11), 1236-1264; doi:10.3390/ph5111236
Received: 27 September 2012; in revised form: 7 November 2012 / Accepted: 14 November 2012 / Published: 20 November 2012| Download PDF Full-text (325 KB) | Download XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Review
Title: Targeting the PI3 Kinase Signaling in Virus-Associated Cancer
Authors: Mariko Tomita and Shuji Tomita
Affiliation: Department Pathology and Oncology, Graduate School of Medical Science, University of the Ryukyus, Japan;
E-Mail: firstname.lastname@example.org (M.T.)
Abstract: The Phosphoinositide 3-kinases (PI3K) are a family of lipid kinases, that integrate extracellular signal proteins such as growth factors and nutrients, promote cell growth and survival. This signaling pathway is often activated in a variety of human cancers. Thus, PI3K signaling pathway seems to be a good target of cancer treatment and inhibitors of this pathway are developing as anti-cancer agents. In this review, we summarize roles of PI3K signaling in cancers which are caused by human viruses, such as human papilloma virus, hepatitis B virus, hepatitis C virus, Kaposi’s sarcoma-associated herpes virus, Epstein-Barr virus, and human T-cell leukemia virus type. We also discuss the data supporting the use of PI3K inhibitors in these cancers.
Last update: 18 May 2012